Founded in 2011, OMNI Pharma（OMNI）is an innovative pharmaceutical company focusing on drug delivery technologies. 

Technical focus and expertise: The company is dedicated to the research and development, and industrialization of inhalation formulations, owns powerful research and develops strengthand technological superiority. At present, the company has the capability of independent R&D and manufacturing of metered dose inhaler, dry powder inhaler, inhaled nebulizing solutions and nasal spray, and has a proprietary design platform incorporating breathing apparatus. 

Government support: The dry powder formulation project has been designated the National Key Science and Technology Project and received strong government support. Since the beginning of 2019, a number of the company’s projects have entered the clinical trial stage, with the expectation that international-level inhalation formulations independently developed by China will soon be launched in domestic market.

Product coverage：With treatment focus on asthma and chronic obstructive pneumonia (COPD), the company has product pipelines covering all key areas in this field, and the market potential is huge. 

Marketing Network: Excellent brand building, with a strong network of experts and doctors; Fast market access, covering most hospitals, retail pharmacies and e-commerce platforms; Independent innovation of digital SSaaS platform, improve work efficiencyand ensure compliance operation.

Global Vision: The company is focusing on the expansion of overseas markets, together with domestic and foreign pharmaceutical companies and partners. The company is also actively promoting the launch of its products in mature markets, such as Europe and the U.S., as well as the China market, 

"Made in China, for the World": Our standard and goal is to provide high-quality and affordable drugs for people across China and beyond.